Access to the PDF text

Archives de pédiatrie
Volume 23, n° 12S
pages 1247-1253 (décembre 2016)
Doi : 10.1016/S0929-693X(17)30062-3
Nouvelles thérapeutiques ciblant le canal chlorure dans la mucoviscidose
New therapeutic developments in cystic fibrosis

Figure 1

Figure 1 : 

Mécanismes physiologiques: synthèse, maturation/migration intracellulaire et fonction de la protéine CFTR.

Figure 2

Figure 2 : 

Symptômes en fonction de la proportion de protéine CFTR active. Combien faut-il de CFTR?

3o% d’activité CFTR est associée à une réduction des symptômes.

Figure 3

Figure 3 : 

Classes de mutations du gène CFTR , conséquences physiopathologiques et cibles thérapeutiques.

EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline